Orchid Pharma (ORCHPHARMA.BO) Earnings Analysis

Orchid Pharma (ORCHPHARMA.BO) next reports earnings on 2026-08-06, consensus EPS 3.6 INR. Last quarter (2026-05-25) it beat with EPS 4.7 INR vs 3 INR est (+56.7%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 238.98.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ORCHPHARMA.BO next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate3.6 INR
Revenue estimate2.31B

ORCHPHARMA.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-254.7 INR3 INR+56.7%Beat
2026-02-114.1 INR-0.3 INR+1466.7%Beat
2025-08-122.9 INR3.7 INR-21.6%Miss
2025-05-264.4 INR4.4 INR0%Beat
2025-02-124.25 INR6.3 INR-32.5%Miss
2024-11-115.4 INR4 INR+35%Beat
2024-08-125.8 INR6.9 INR-15.9%Miss

Beat rate: 4/7 (57%) over reported quarters with consensus data.

ORCHPHARMA.BO valuation and analyst view

Trailing P/E238.98
Trailing EPS4.014 INR
Price / book3.77
Dividend yield0.00%
Market cap50.89B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Orchid Pharma (ORCHPHARMA.BO)'s next earnings date?

Orchid Pharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 3.6 INR and revenue estimate of 2.31B.

Did ORCHPHARMA.BO beat earnings last quarter?

In its 2026-05-25 report, ORCHPHARMA.BO posted EPS of 4.7 INR versus a 3 INR estimate — a beat of 56.7%.

What is ORCHPHARMA.BO's earnings track record?

Over the last 7 reported quarters with consensus data, ORCHPHARMA.BO beat estimates 4 times (57%).

What is ORCHPHARMA.BO's current P/E ratio and EPS?

ORCHPHARMA.BO trades at a trailing P/E of 238.98 on trailing EPS of 4.014219785421268 INR.

What do analysts rate ORCHPHARMA.BO?

ORCHPHARMA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.